Proportion of participants with adverse effects ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with adverse effects ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with adverse effects ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects of treatment Overall incidence of complications · people with lateral patellar dislocation
It is very uncertain whether surgical changes adverse effects of treatment Overall incidence of complications compared with non‐surgical treatment (very low certainty).
1 finding from 1 review
Side effects or other adverse events · adults with antisocial personality disorder
1 finding from 1 review
Proportion of participants with adverse effects ‐ measured over 8 weeks · chronic palmoplantar pustulosis
1 finding from 1 review
Adverse effects: neurological, extrapyramidal UKU (events) Medium‐term · people in the prodromal stage of psychosis
Group A: omega‐3 fatty acids showed no clear difference in adverse effects: neurological, extrapyramidal UKU (events) Medium‐term compared with placebo (low certainty).
1 finding from 1 review
Proportion of participants with adverse effects ‐ measured over 8 weeks · chronic palmoplantar pustulosis
Topical vitamin D derivative showed no clear difference in proportion of participants with adverse effects ‐ measured over 8… compared with placebo (moderate certainty).
1 finding from 1 review
Proportion of participants with adverse effects ‐ measured over 8 weeks · chronic palmoplantar pustulosis
1 finding from 1 review
Any other adverse effects of the interventions, such as gingival disease and demineralisation · Young people aged 9 to 14 years diagnosed with one or both palatally displaced permanent maxillary canines (PDC)
The review found no eligible studies for this question.
1 finding from 1 review
Any other adverse effects of the interventions, such as gingival disease and demineralisation · Young people aged 9 to 14 years diagnosed with one or both palatally displaced permanent maxillary canines (PDC)
The review found no eligible studies for this question.
1 finding from 1 review
Proportion of participants with adverse effects ‐ measured over 8 weeks · chronic palmoplantar pustulosis
It is very uncertain whether etretinate changes proportion of participants with adverse effects ‐ measured over 12… compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Proportion of participants with adverse effects ‐ measured over 8 weeks · chronic palmoplantar pustulosis
It is very uncertain whether etretinate with PUVA therapy as co‐intervention changes proportion of participants with adverse effects ‐ measured over 20… compared with placebo with PUVA therapy (very low certainty).
1 finding from 1 review
Proportion of participants with adverse effects ‐ measured over 8 weeks · chronic palmoplantar pustulosis
It is very uncertain whether etretinate changes proportion of participants with adverse effects ‐ measured over 12… compared with PUVA therapy (very low certainty).
1 finding from 1 review
Proportion of participants with adverse effects ‐ measured over 8 weeks · chronic palmoplantar pustulosis
Alitretinoin showed no clear difference in proportion of participants with adverse effects ‐ measured over 24… compared with placebo (moderate certainty).
1 finding from 1 review
Side effects or other adverse events · participants at risk of high altitude illness
Acetazolamide may leads to higher adverse events: side effects‐ Follow‐ up: From arrival to 24 hours… compared with placebo (low certainty).
1 finding from 1 review
Side effects or other adverse events · participants at risk of high altitude illness
1 finding from 1 review
Percentage of participants with adverse effects and severe adverse effects · guttate psoriasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found